RE: The future revenue stream of Iclarim (if any)2 Jun 2021 21:17
Page 152 of the Readmission Document states:
17.9 Sale agreement, dated 24 February 2021, with Orange Avenue Technologies LLC
"The Company entered into a stock purchase agreement on 24 February 2021 with Orange, pursuant to which Orange acquired the entire issued share capital of Motif, Inc. Orange is wholly owned by John Palmer, the President of Tamarack Associates Inc. the company which was engaged by the Company to facilitate the sale of iclaprim and other assets of Motif, Inc. in January 2020.
In accordance with the terms of the agreement, the Company received US$10.00 for the transfer of the shares of Motif, Inc. In addition, in the event that Motif, Inc. generates revenue from its iclaprim assets which exceeds the amount of the company’s outstanding liabilities, Motif, Inc. shall retain the first US$250,000. Any revenue generated above this threshold will be split between the Company and Motif, Inc. at a ratio of 90:10 and will be paid within 30 days after the close of the quarter in which any revenue is earned. The Company has acknowledged that it will have no future participation in any gains, losses, profits or distributions related to the shares of Motif, Inc."
Still no mention of who gets the Iclaprim revenue if/when it happens??